Simvastatin for the prevention of exacerbations in moderate-to-severe COPD - Wikidata - wikimedia - TriplyDB

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD

http://www.wikidata.org/entity/Q34661935

about

Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease Exacerbations of COPD The role of airway macrophages in apoptotic cell clearance following acute and chronic lung inflammation The Role of Innate and Adaptive Immune Cells in the Immunopathogenesis of Chronic Obstructive Pulmonary Disease The stats are in: an update on statin use in COPD COPD and its comorbidities: Impact, measurement and mechanisms Positioning new pharmacotherapies for COPD Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.Repurposing Treatments to Enhance Innate Immunity. Can Statins Improve Neutrophil Functions and Clinical Outcomes in COPD?Current and Emerging Uses of Statins in Clinical Therapeutics: A Review Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection.Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD).Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.In-hospital and one-year mortality and their predictors in patients hospitalized for first-ever chronic obstructive pulmonary disease exacerbations: a nationwide population-based study Multicenter study comparing case definitions used to identify patients with chronic obstructive pulmonary disease Cardiovascular and inflammatory effects of simvastatin therapy in patients with COPD: a randomized controlled trial No significant detectable anti-infection effects of aspirin and statins in chronic obstructive pulmonary disease Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study.The Effect of Statins on Blood Gene Expression in COPD.Impact of Statins on Gene Expression in Human Lung Tissues.Inflammatory markers and mortality among US adults with obstructive lung function.Simvastatin Suppresses Airway IL-17 and Upregulates IL-10 in Patients With Stable COPD.The effect of statins on chronic obstructive pulmonary disease exacerbation and mortality: a systematic review and meta-analysis of observational research Effect of ATorvastatin On Chronic subdural Hematoma (ATOCH): a study protocol for a randomized controlled trial.Lovastatin for the Treatment of Adult Patients With Dengue: A Randomized, Double-Blind, Placebo-Controlled Trial Resolvin D1 prevents smoking-induced emphysema and promotes lung tissue regeneration β-Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βLOCK COPD): a randomised controlled study protocol Statins and morbidity and mortality in COPD in the COMIC study: a prospective COPD cohort study.The association of statin therapy with the risk of recurrent venous thrombosis.Simvastatin up-regulates adenosine deaminase and suppresses osteopontin expression in COPD patients through an IL-13-dependent mechanism A prospective, randomized study: Evaluation of the effect of rosuvastatin in patients with chronic obstructive pulmonary disease and pulmonary hypertension Risk of cardiovascular events after initiation of long-acting bronchodilators in patients with chronic obstructive lung disease: A population-based study.Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis.Examining the role of ABC lipid transporters in pulmonary lipid homeostasis and inflammation.Association Between Statin Medications and COPD-Specific Outcomes: A Real-World Observational Study.Statins as adjunct therapy in COPD: how do we cope after STATCOPE?Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management.Animal models for anti-emphysema drug discovery.An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease.Preventive Role of Tetraspanin CD9 in Systemic Inflammation of Chronic Obstructive Pulmonary Disease.

P2860

Q26741051-6845E4AD-A635-421E-AB86-D39DD2D0D666 Q26764891-1142C254-D1F6-4768-9B51-D7F12654BCEE Q26767123-203E4433-FC47-403F-BBC0-292E3F29C4D2 Q26771902-8FEC7FB6-F7A6-4565-B303-F7F2647AAF31 Q26778906-5B091875-2AFC-4C95-8120-24EE989A12E3 Q26786812-AE673CE0-8123-49CC-937C-E579D19A5573 Q26798659-D188F2C4-C28B-4284-9602-64D1D95D8422 Q27348844-30464F27-7A1D-4397-9DC6-4C638BF14AC6 Q28066773-A533867B-CC33-453C-ACCF-6C21DA8C7CA9 Q28076346-F9BB2C6E-04BD-452C-A491-B9492206BAB2 Q33623532-43D16051-D795-4B22-B3AF-861A339CEE7A Q33814586-C81EB9F4-6278-4393-B7A3-5AD1E63D5A26 Q34550471-2A81EF90-DE2D-4143-B9E8-EF3782CC8BBB Q34663530-CB717639-597E-4B6F-A8AF-3B5F4FD52C8B Q34986952-661507E8-9EC7-487D-BC19-BC062FF52BEA Q35063739-3B55358C-2FA0-4659-9E06-E064E277A86A Q35197476-98B16345-A508-4226-AA68-A36D62B7055A Q35675649-C73029CB-0C67-491F-8837-7C40FB227F5F Q35804958-04E2A9BF-32F3-4181-BB7E-653CF52DC1DF Q35831665-50C1A224-CCEE-4EBC-BD5E-2F7970A20E7F Q36036012-D44FC663-A55B-4B2C-9E71-08A2A589F060 Q36243216-E1A6A89A-084B-42D0-AC3C-AA6317448D02 Q36265724-06EB9BE0-579E-4019-92C4-D1EA20FC6E69 Q36298592-D593CAF6-649F-4519-9D4F-D7DE06E6106B Q36497872-469CCA47-56AB-40F0-BBCD-56D7CF414040 Q36961495-4260EC72-640B-4367-B02E-0D46C999A6B5 Q37006972-A2AF97AD-873B-4E55-85CD-D833E28F1E6C Q37063674-B45E4970-C097-42D2-8487-9A96C5C53647 Q37138335-FEFD8CA7-404F-4F98-89F6-0297E4FE2A9C Q37203479-DF087775-47A5-45C8-91CB-2FBC3E0AF75A Q37311952-B3730E59-02FE-42BF-B3AE-CE79017A6188 Q37315758-6CD8C5E9-2290-43E2-B83E-789C6D4A2695 Q37616955-D9A0465A-1454-4A23-A01E-5FE4BDC12D98 Q37671430-628CF9E8-9632-479F-9192-C533F5AB4966 Q37675233-71260899-080E-4BD4-908B-AAFE410DDC02 Q38228514-5B07330C-1924-4358-B121-26D9C28F779C Q38342003-E62445B7-7449-4831-8CA5-FE622D97A128 Q38363949-6FA86440-947F-4BD8-8B7C-F242AF0A0347 Q38399184-C91B30D0-DBE7-4BB0-A911-63AD25018E4C Q38588362-8A612CFB-AD35-45BF-B694-7E87A5695344

P2860

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD

http://www.wikidata.org/entity/Q34661935

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD

@ast

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD

@en

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD

@nl

type

label

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD

@ast

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD

@en

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD

@nl

prefLabel

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD

@ast

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD

@en

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD

@nl

P1433

Q34661935-4A9FF458-8E57-4527-93B0-345CE4927FD3

P1476

Q34661935-1F4B4C11-F8C9-46C0-8B5F-902ECF5258FC

P2093

Q34661935-007FFB3D-E7D7-411C-A24C-43AD95CF6852

Q34661935-01104452-8887-4A20-8AAA-2C6034F4969C

Q34661935-0F3E6CD7-9C06-4E21-A3A3-8A6C70C9505B

Q34661935-1A2CB898-1FBE-4762-A49A-E0F7A0625B34

Q34661935-1DA9E4BA-3964-434F-A44B-918C22678B3F

Q34661935-3B7E4DE5-224B-4FF0-9F30-D57A04CDCE92

Q34661935-3E0F3960-B7A1-4DD7-8C33-32B28FA98AFF

Q34661935-43955F6F-9590-419E-A82A-9DDC40BE6CA0

Q34661935-578E0CCA-B42C-4BAA-B2E2-302E9617510E

Q34661935-580CBC7B-CF64-4BC1-90CC-8ECA3D315397

P2860

Q34661935-18D7184B-31DD-4029-9A52-5E468805EBE4

Q34661935-1E2D7A61-4868-4E26-843C-B627ACBD5630

Q34661935-21B9E877-F6E9-4045-8AE0-5D7E4DD5A260

Q34661935-223776CA-7535-427E-BE58-7528BD337662

Q34661935-231FFA14-E710-4B22-B60D-05281D653FA9

Q34661935-232B1C74-3934-42CF-8A8E-5D826F64A69A

Q34661935-298D4849-0950-4A6E-96EA-01A172783351

Q34661935-2D881BF2-0404-4D01-A9BE-D7D62931D5A2

Q34661935-2D8CFE0B-F447-40EF-84C7-71ABFC13F4EE

Q34661935-347E33AC-CF0D-46CC-8A1F-7458BCD33E5D

P304

Q34661935-A0AC8A5A-0398-44A4-BC65-0E73CF396BE1

P31

Q34661935-103D2936-6362-4F99-8547-41777839FD35

P356

Q34661935-F3F750EF-8989-4236-B144-D934BEC02031

P407

Q34661935-4F4508CB-064D-402E-9DF9-7E1B2DBC8B5E

P433

Q34661935-DA66E3DE-8DDE-4768-810C-542777D0CD48

P478

Q34661935-E1A59A54-571A-4744-9F7A-0C931DDE31D0

P50

Q34661935-22F13840-5D34-4AEF-94E7-61F3654F46BA

Q34661935-BD730EF6-2819-43E9-B90A-4F69F0B27603

Q34661935-DAA0A729-30CA-4601-8B73-A8B75CCAF857

P577

Q34661935-93080194-CA36-4A46-B331-F43AF74D2345

P698

Q34661935-0397D423-8B04-4CD2-B516-6EA7DF8DB091

P932

Q34661935-12740B0F-9C41-4CE1-B046-768A644646C4

P356

P1433

The New England Journal of Medicine

P1476

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD

@en

P2093

Barry Make

http://www.w3.org/2001/XMLSchema#string

COPD Clinical Research Network

http://www.w3.org/2001/XMLSchema#string

Canadian Institutes of Health Research

http://www.w3.org/2001/XMLSchema#string

Dennis E Niewoehner

http://www.w3.org/2001/XMLSchema#string

Don D Sin

http://www.w3.org/2001/XMLSchema#string

Fernando J Martinez

http://www.w3.org/2001/XMLSchema#string

George R Washko

http://www.w3.org/2001/XMLSchema#string

Gerard J Criner

http://www.w3.org/2001/XMLSchema#string

Helen Voelker

http://www.w3.org/2001/XMLSchema#string

J Allen D Cooper

http://www.w3.org/2001/XMLSchema#string

P2860

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

Spirometric reference values from a sample of the general U.S. population

The MOS 36-ltem Short-Form Health Survey (SF-36)

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

Standardisation of spirometry

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

Direct costs of chronic obstructive pulmonary disease among managed care patients.

P304

2201-2210

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1403086

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

370

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey L. Curtis

P577

2014-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24836125

http://www.w3.org/2001/XMLSchema#string

P932

4375247

http://www.w3.org/2001/XMLSchema#string